Effects of Anserine/Carnosine Supplementation on Mild Cognitive Impairment with APOE4

• Published in: Nutrients Vol. 11; no. 7; p. 1626
• Main Authors: Masuoka, Nobutaka, Yoshimine, Chitose, Hori, Marie, Tanaka, Mieko, Asada, Takashi, Abe, Keiichi, Hisatsune, Tatsuhiro
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 17.07.2019; MDPI
• Subjects: Aged; Aged, 80 and over; Alzheimer disease; Alzheimer's disease; Amyloid beta-Peptides - blood; anserine; Anserine - administration & dosage; Apolipoprotein E4 - metabolism; Apolipoproteins; Blood-brain barrier; Brain research; carnosine; Carnosine - administration & dosage; cognition; Cognition & reasoning; Cognition - drug effects; Cognitive ability; cognitive disorders; Cognitive Dysfunction; Dementia; Dietary Supplements; Double-Blind Method; elderly; Female; Humans; Laboratories; Male; Memory; Middle Aged; Musculoskeletal system; Older people; placebos; protective effect; Japan; mild cognitive impairment (MCI); Alzheimer’s disease; cognitive functions; APOE4; anserine and carnosine; randomized controlled trial (RCT)

Background: Oral supplementation of anserine/carnosine helps preserve cognitive functions in healthy older adults. Mild cognitive impairment (MCI) is a transition between cognitive-normal and dementia. Therefore, it needs to investigate whether anserine/carnosine supplementation (ACS) has effects on...